


Global impact of COVID-19 and lockdowns on POC HbA1c testing

Through the ups and downs of the COVID-19 pandemic, regions across the globe have witnessed a serious impact on HbA1c testing for diabetes diagnosis and monitoring. With deprioritization of testing in healthcare facilities and the increasing volume of COVID-19 patients requiring treatment, point-of-care testing for diabetes has taken a hit. While the reopening of countries is not uniform, studies suggest that markets may likely see an increase of diabetes populations in worse glycemic control compared to pre-pandemic metrics and also an increase in the volume of patients who require tests such as HbA1c and ACR.



1. Maren SF, Harvey WK, James BM, et al. Consequences of the COVID-19 pandemic: reduced hemoglobin A1c diabetes monitoring. Population Health Management. 2021;24(1). DOI: 10.1089/pop.2020.0134
2. Anu S, Dina NG, Allison BC, et al. The effect of the Covid-19 shutdown on glycemic testing and control. Clinica Chimica Acta. 2021;519:148-52.
3. Ledford CJW, Roberts C, Whiesnant E, et al. Quantifying worsened glycemic control during the COVID-19 pandemic. Journal of the American Board of Family Medicine. 2021;34:S192. doi: 10.3122/jabfm.2021.S1.200446
4. Mathew JC, Alison KW, Lalantha L, et al. Impact of COVID-19 on diagnoses, monitoring and mortality in people with type diabetes in the UK. The Lancet. 2021;19. https://doi.org/10.1016/S2213-8587(21)00116-9
5. Jaideep K, Sushil J. Observational study on effect of lock down due to COVID 19 on HbA1c levels in patients with diabetes: experience from Central India. Prim Care Diab. https://doi.org/10.1016/j.pcd.2020.12.003
6. Imai C, Hardie R-A, Thomas J, Wabe N, Georgiou A. The impact of the COVID-19 pandemic on general practice-based HbA1c monitoring in type 2 diabetes. General Practice Snapshot. 2021;5. https://doi.org/10.25949/Q9BE-BJ06

Limitations: Publications and research on this topic are limited but steadily increasing in number. This communication is not intended to be exhaustive or definitive. Individual observations and studies listed here may have independent limitations.
Published by Siemens Healthcare Diagnostics Inc. - Order No. 40-21-DX-974-76 - 08-2021 - © Siemens Healthcare Diagnostics Inc., 2021